Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program ; volume:19 ; number:1 ; day:7 ; month:1 ; year:2019 ; pages:1-10 ; date:12.2019
BMC cancer ; 19, Heft 1 (7.1.2019), 1-10, 12.2019
- Urheber
-
Heidenreich, Axel
Gillessen, Silke
Heinrich, Daniel
Keizman, Daniel
O’Sullivan, Joe M.
Carles, Joan
Wirth, Manfred
Miller, Kurt
Reeves, John
Seger, Monica
Nilsson, Sten
Saad, Fred
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-018-5203-y
- URN
-
urn:nbn:de:101:1-2019022008051211571107
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Heidenreich, Axel
- Gillessen, Silke
- Heinrich, Daniel
- Keizman, Daniel
- O’Sullivan, Joe M.
- Carles, Joan
- Wirth, Manfred
- Miller, Kurt
- Reeves, John
- Seger, Monica
- Nilsson, Sten
- Saad, Fred
- SpringerLink (Online service)
Ähnliche Objekte (12)
Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases
Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases
The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223
Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223
Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases
Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases
The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223
Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223
Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases
Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases
The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223